At one point, we thought that the COVID-19 pandemic was getting behind us. After being locked down in our homes and distanced from our loved ones for more than a month, case counts started declining. The economy began to reopen. The skies were incredibly blue.
Unfortunately, as we started to venture out of our homes, dark clouds rolled in once again. Today, COVID-19 cases are skyrocketing, reaching record daily numbers in various states across the country.
The need for viable vaccines and treatments has never been more clear.
The good news is that there are several companies working to develop vaccine and treatment options. That’s not only good for the global community and the global economy, it’s great for investors.
At the end of the day, as companies create viable vaccine and treatment options, they will be met with incredibly high demand, opening the door to strong revenue opportunities. That means that publicly traded companies working to fight the COVID-19 pandemic offer up a compelling opportunity for investors.
After all, buying in now while vaccines and treatments are under development gives investors a discount on the gains that could be seen as these options hit the market.
At the same time, as consumers stay home, the dynamics of business are changing, opening the door to big surges in online retail, cloud services, and other sectors that cater to at-home consumers.
Nonetheless, investing in the COVID-19 space is just like investing in any other space. Not all stocks are created equally and making the wrong investments could lead to a significant loss of capital.
With that said, here are five stocks that I believe are poised to benefit from the development of COVID-19-related products.
Peloton Interactive (PTON): As Gyms Lose Big, At Home Workout Gear Is A Big Gainer
Peloton Interactive is the at-home exercise company. The company sells a long list of exercise equipment ranging from stationary bikes to treadmills, accessories and clothing. However, equipment is only a piece of the company’s business.
The “Interactive” in the name Peloton Interactive, comes from the company’s media streaming products. Peloton’s workout equipment comes equipped with a screen. This screen opens the door to a wide range of streaming exercise classes, giving the consumer a unique, in-home, workout experience.
As the COVID-19 pandemic continues to weigh heavy across the United States, the gym is the last place that people want to be seen. Not only is it difficult to maintain social distance in a gym atmosphere, as consumers workout, they breathe heavily, increasing chances of transmission should someone with COVID-19 be in the building with you.
The millennial generation is the one that works out more than any other generation in the past. As information becomes more readily available with regard to health and lifestyle, this generation of consumers becomes more and more active in staying in shape and eating well.
As such, staying away from the gym won’t stop the workout. With gyms closed, workout equipment companies have seen a big boost in sales, and there’s a strong chance that this trend will continue. As such, it’s no surprise to see that Peloton Interactive stock is up well over 100% year to date.
Vitro Diagnostics (VODG): A COVID-19 Treatment Play That Should Not Be Ignored
Vitro Diagnostics is a stem cell company that’s anything but a spring chicken in the biotechnology industry. The company’s proprietary process to the production of stem cells is second to none, giving them the ability to produce its life-saving AlloRx stem cells faster and for a lower cost than anyone in the industry.
For several years, the company’s AlloRx stem cells have been used in the production of treatment options for several ailments, including, but not limited to, MS, Crohn’s disease, osteoarthritis, heart disease, brain injury, autism, stroke, Parkinson’s disease, and Alzheimer’s disease.
The last ten years of the company’s history have been the research and development phase of the AlloRx Stem Cells™. The last few years the company has sold its AlloRx stem cells to medical tourism clinics under local authority. That’s starting to change as the company is now directing its efforts to the US market with early FDA safety trials commencing with its COVID-19
Emergency use authorization IND partnered with GIOSTAR along with the companies own
IND application in process.
Stem cell therapies have shown incredible promise in COVID-19 patients, and Vitro Diagnostics seized the opportunity. As such, it has begun work to prove that its AlloRx stem cells are not only safe, but effective in the treatment of severely ill COVID-19 patients, and it’s having incredible success in doing so.
On July 14, 2020, Vitro announced the results from the first COVID-19 patient treated with AlloRx stem cells. Prior to treatment with AlloRx stem cells, the patient had a very grim prognosis. Severe COVID-19 led to the degradation of function in multiple vital organs, assisted breathing requirements, and a coma.
While fighting COVID-19, the patient also experienced a stroke.
Doctors provided every treatment they knew to no avail. However, shortly after treatment with AlloRx stem cells, the patient began to recover. At last update, he had no severe COVID-19-related symptoms and was able to walk, talk, and eat again. The patient has recovered from COVID-19 and now is undergoing physical therapy as a result of the stroke incurred due to COVID-19 but the virus has been defeated.
If that’s not valuable, I don’t know what is. As such, VODG stock should be on your watchlist.
Amazon.com (AMZN): The Shop At Home Powerhouse
Even before COVID-19 took center stage, Amazon.com was THE eCommerce website. The household name is the go-to source for many when it comes to the purchase of day to day items, technology, and more.
While COVID-19 has thrown a wrench in the plans of retail establishments, online sales are booming. Consumers, afraid to shop in crowded stores, are now more likely to shop online than in store.
This is leading to a dramatic increase in Amazon.com sales, and therefore, making the stock price fly. However, online shopping isn’t the only driving factor for the strong growth we’ve seen in Amazon.com stock.
The company is the owner of the subsidiary, Amazon Web Services, a cloud computing company. Again, prior to the pandemic, AWS was doing overwhelmingly well, seeing a rapid increase in adoption and further cementing its leadership in the space.
However, with COVID-19 in place, demand for cloud computing has never been higher. At the end of the day, more and more people are working from home, and that requires safe, secure ways to have conferences, share documents, and more. The cloud seems to be that solution.
So, not only is Amazon.com benefiting from its leadership in eCommerce in the face of the COVID-19 pandemic, it is a big winner in the cloud computing space. No wonder the stock has climbed from around $1,900 per share to more than $3,100 per share this year. If that’s not enough to convince you to keep an eye on AMZN stock, I don’t know what is.
iBio (IBIO): A Key Player In Vaccines
When it comes to vaccines, the world seems to be looking to Moderna and Inovio as the leaders in space, and for good reason. They are the furthest along in the development process and hope to have a vaccine ready by the end of the year.
Nonetheless, there are some concerns. The vaccines require multiple doses. Moreover, no single company can manufacture enough of the vaccine to keep up with demand at the moment. As such, multiple players are going to be needed, leaving plenty of room for iBio.
With that said, iBio has several strategic advantages in the vaccine space. First and foremost, it is one of very few companies that has multiple development programs, assessing multiple vaccine options. Moreover, the vaccines being developed are expected to be single-dose vaccines.
It’s also worthwhile to look at the company’s partner, CC-Pharming. The partnership with the Chinese company not only opens doors to potential marketing in mainland China, CC-Pharming already has experience in the production of a viable vaccine for a sister strain of the coronavirus that caused the pandemic.
Beyond that, iBio is the owner of the FastPharming Facility, a facility commissioned by the United States government several years ago. The idea behind the FastPharming Facility was the ability to produce vaccines and other biologic agents at a rapid pace in the face of a pandemic.
So, not only is there room for an iBio vaccine, even if it’s not the first to hit the market, the company has manufacturing capabilities unmatched by any other player in the space. As such, IBIO stock should be watched incredibly closely.
Abbott Labs (ABT): A Leader In Diagnostics
Finally, we have Abbott Labs. As the coronavirus started to hit the United States hard earlier this year, Abbott Labs jumped into action, rolling out several COVID-19 diagnostics tests.
In fact, by late March, Abbott Labs had already received Emergency Use Authorization from the FDA for its ID NOW test. The test has been met with incredibly high demand because it provides results faster than any other COVID-19 test.
As the COVID-19 pandemic continues to spread, we seem to be getting testing under control. However, the speed of results is still lagging. The fact that Abbott Labs has the test that provides the fastest results, it’s likely to see continued gains in demand.
However, COVID-19 isn’t the only space Abbott is targeting. In fact, it recently received FDA clearance for a new version of its continuous glucose monitoring system. The new system now supports integration with other medical devices.
With all of the success that Abbott Labs has had in COVID-19 and other areas, it only makes sense that we will see strong revenue growth ahead, making this an exciting stock for investors to watch.
COVID-19 has changed the way we live, there’s no question about it. While the United States reopens, we are walking out into a brand new world. We can look at this new world as a burden, or decide to look for the opportunity.
The fact of the matter is that while some businesses are struggling, others are doing great. At the same time, opportunities are emerging in biotechnology like never before. I believe that the stocks mentioned above represent these types of opportunities.
Nonetheless, before making any investment decision, it’s important to do your research. As mentioned above, not all COVID-19 stocks are created equally!
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Vitro Diagnostics, CNA Finance has been hired for a period beginning on 6/26/20 and ending on 8/26/20 to conduct digital advertising and marketing and publicly disseminate information about VODG via Websites and Email. We have an agreement and have been paid six thousand dollars via check to cover the cost of content production and publication for the first month. We expect to receive another payment of six thousand dollars to cover costs of services for month two.This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Vitro Diagnostics has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.